By Dental Tribune International

GOTHENBURG, Sweden: W&H, one of the world’s leading manufacturers of dental precision instruments and devices, has acquired medical technology company Osstell, known for its implant stability measurement and osseointegration monitoring products. The step is part of W&H’s strategy for surgical expansion, with the aim of broadening its competence and strengthening its position as a leader in the field of implantology.

Osstell’s technology helps dentists around the world to make dental implant treatments as safe and predictable as possible. By measuring the stability of implants objectively and non-invasively using ISQ (Implant Stability Quotient) technology, clinicians can improve patient confidence and comfort. Founded in 1999, Osstell developed the patented ISQ technology and its products are sold in more than 50 markets globally, with operations in Sweden and the US.

“Osstell and W&H have cooperated very successfully in the past, so it is a natural step that Osstell now becomes a part of W&H. As such, we get the opportunity for stronger and broader global representation, as well as greater delivery capacity—always with the aim to serve our customers and users with even better products and services as well as helping them to provide best practice services to their customers—the patients. Patients’ well-being is always the top priority,” said OsstellOsstell CEO Jonas Ehinger.

“The aim is to further expand our expertise and thus strengthen our position as a specialist in oral implantology. The specialised company with its structure fits perfectly to the character of a family business, which is why we are confident that Osstell is a good fit and will become a valuable member of our W&H family,” said W&H President and CEO Peter Malata.

Currently, Osstell technology is available in a range of products, including in W&H’s latest generation Implantmed, an integrated solution that supports dental implant clinicians in their everyday practice. The ISQ measurements allow clinicians working with implants to make decisions based on reliable and objective stability values when determining the course of treatment for each patient.